Noveome’s other programs will help demonstrate the significant platform capability of ST266

ST266 has been shown to be safe and can be delivered via diverse routes of administration: topical (dermal, oral mucosa, ocular), parenteral, intranasal, intravenous, oral gavage, intracameral. In addition, its anti-inflammatory, neuroprotective, and other properties suggest that it may be useful for the treatment of a wide range of indications beyond the eye.

Radiation Burns

Radiation burns of the skin are a common side effect of external beam radiotherapy for the treatment of cancer. These dermal burns are often severe, particularly when treating head-and-neck cancer or pelvic cancer, such that radiation treatments are sometimes interrupted to allow the patient time to recover.

When radiation therapy is interrupted, especially in head-and-neck cancer, the mortality may go up. There is no ideal preventive therapy to reduce the severity of radiation burns of the skin. ST266 has been shown to be anti-inflammatory and offers the possibility of reducing the severity of radiation burns, thereby lessening the pain, and thus improving survival by preventing the need for a break in the treatment regimen. Noveome sponsored studies in radiation burns received support from the U.S. Department of Defense and the Commonwealth of Pennsylvania.

Periodontal Disease

Severe periodontitis is a problem that affects 3.5 million Americans and lacks adequate therapy. Periodontitis is characterized by an acute inflammatory reaction that, if unresolved with failure of tissue to return to homeostasis, results in tissue destruction and chronic inflammation. Severe periodontitis remains the primary cause of tooth loss.

Resolution of inflammation in periodontitis with ST266 may reduce injury, promote healing, and restore tissue homeostasis.

Preclinical experiments have shown that ST266 reduces inflammatory cytokines, restores lost bone and resolves inflammatory infiltrates. In a Phase 2 clinical study sponsored by Noveome, ST266 resulted in a statistically significant reduction in inflammation by day 15 and was shown to be safe and well tolerated. Noveome sponsored studies in periodontal disease received support from the U.S. Department of Defense.